About b.next
Summary
b.next is a San Francisco synthetic-cell company founded in 2023 by Stanford PhDs who helped launch US Build A Cell.
Shared infrastructure, not lone papers.
Reproducing a result felt like a full project, so b.next exists to make synthetic-cell work composable across labs.
We believe that no single organization has the expertise required to realize the full potential of synthetic cells.
Make interoperable synthetic cell engineering possible with collaborative tools, validated specifications, and standardized methods.
Three-part strategy.
Open Core (specs, methods, Nucleus), Physical Infrastructure (reagents, hardware, automation), and Applications that translate synthetic cells into sensing, health, and other uses.
reproducing a paper felt like a full research project.
My dream is to bring the creativity and collaboration of software engineering to bioengineering
Progress is already measurable.
105 Cytosol kits shipped, 21 labs using Cytosol, 42 Nucleus DevNotes, and 13 collaborating labs in the US and UK.
Funded as public scientific capacity.
Grants and programs from Schmidt Sciences, Astera ($4.9M), Sloan, DARPA, NSF, and ARIA underwrite open PURE, workshops, and AI-scientist R&D.
Leadership comes from Build-a-Cell.
Akshay Maheshwari, Anton Jackson-Smith, Anton Molina, and Jon Calles bring Stanford synthetic-cell and open-hardware practice into a company form.
Read the original ↗Save to your Sponge
Summarized with Sponge. Quotes are the author’s own words.